



A Note from REPRIEVE Leadership: Partners in REPRIEVE



We would like to thank you for your continued contribution to REPRIEVE. We are happy to share the exciting news that we are half-way to completing enrollment for the trial. As of this month, REPRIEVE has enrolled approximately 3,250 participants across the United States, Canada, Brazil, South Africa, Thailand, and Botswana. The REPRIEVE participant community is a diverse group in terms of age, sex, race, and ethnicity and we expect results to be meaningful and applicable to people living with HIV.

April marks the beginning of our 3rd year of enrollment in REPRIEVE and there are several important goals

we would like to share with you. The most important goal involves you! While it is impressive that we are half way to our enrollment milestone of 6,500 participants, it is important to ensure that, as a vital participant, you stay engaged in REPRIEVE. Please continue to take your study pills, return for all follow-up visits, and importantly, notify the study team of any changes to your health at every study visit and/or between study visits. Collecting information on whether you have experienced any heart, brain, or blood vessel-related medical care is important. This information will help us to understand whether pitavastatin (study pill) can help prevent heart-related disease among people living with HIV.

We are most grateful for your contributions and dedication to REPRIEVE. We will continue to provide you with updates on the study. As always, feel free to reach out to our study staff with any inquiries and please let us know if there is anything we can do to enrich your experience.

Thank you for making REPRIEVE possible!

Steven Grinspoon, MD
Massachusetts General Hospital
Co-Principal Investigator
REPRIEVE Trial

Pamela Douglas, MD
Duke University
Co-Principal Investigator
REPRIEVE Trial

Follow the latest on REPRIEVE



www.facebook.com/reprievetrials



www.twitter.com/reprievetrials

Meet Other REPRIEVE Participants

REPRIEVE participants are highly motivated individuals forming the future of heart disease prevention in HIV.

Read about current participants' experience in the trial.



"It's really, from my point of view, an **important study** because we're answering important questions about end organ diseases that occurs with aging and inflammation associated with HIV and ART." - Angel Luis Hernández, CAB* member at the University of Puerto Rico CTU



"This was the first study that I decided to participate in. I have been coming into clinic for 19 years. It seemed like an interesting study to see if statin drugs will help cholesterol and heart disease. **I am excited to find a way to reduce heart disease in HIV patients.**" - Shirley Selvage, University of Alabama at Birmingham



"I feel blessed to have the medications we do today and feel like we have that medicine because of past research. **I want to give back and contribute to future research.**" - Wes Taylor, Greensboro, North Carolina CAB*

*CAB stands for Community Advisory Board

Follow YOUR Heart

Did you know?

REPRIEVE's Follow YOUR Heart Campaign was featured by the Women's Heart Alliance Co-Founder, Barbra Streisand, & Director of the National Institute of Allergy and Infectious Diseases, Dr. Anthony Fauci.

In the article, REPRIEVE is highlighted as a unique, well-designed trial that acknowledges the importance of sex differences in heart disease risk among individuals with HIV. This is thanks to the efforts of the unique Follow YOUR Heart Campaign to focus on sex differences in heart disease and HIV and the effort to assure women participate in REPRIEVE!

FAQs

Q: I have been off study pills, but I want to start retaking them. Is this allowed?

A: Absolutely! Restarting study pills is encouraged, provided you weren't asked to stop them by the study staff. The success of REPRIEVE depends on participants taking 1 study pill once daily. Please discuss restarting with the study staff at your site.

Q: What if I move to another state or country? Can I still participate in REPRIEVE?

A: If you are moving, please let REPRIEVE study staff at your site know; the staff member can see if there is a REPRIEVE site located in your destination.

Tips for a healthy heart!


1. Take responsibility for your health, keep all scheduled appointments, take prescribed medications as directed, know your health status.
2. Break the TV/screen habit and replace it with daily exercise.
3. Don't smoke or expose yourself to second-hand smoke.
4. Reduce stress by exercising, getting enough sleep, laughing, and spending time with friends and family who support you.

REPRIEVE Facts


We're celebrating the 2nd year of REPRIEVE!



- REPRIEVE will be the largest trial to date on HIV and heart disease
- There are 110+ sites, in the US, Canada, Thailand, South Africa, Botswana, and Brazil! Sites will soon open in India, Uganda, Zimbabwe, Haiti and Peru.
- 3,250 participants have joined so far, with a goal to enroll 6,500 participants



Women



Race

Join the REPRIEVE CAB!

Building strong relationships and trust between REPRIEVE investigators and the community is crucial to the success of REPRIEVE. Because of this, we are seeking Community Advisory Board (CAB) members from REPRIEVE sites to help members of the general community understand the science of HIV/AIDS and cardiovascular disease, to ensure community concerns are considered, and to serve as a voice for the community and study participants. The REPRIEVE CAB is in its infancy and we need your participation to help us develop it. If you are interested in joining, please email Katie Fitch, MSN at kfitch@partners.org.

Reminders

- Please call your research team if you have any study related questions or to report changes in your health, medications, supplements.
- Please remember to take 1 study pill once a day. If you forget to take your pill on any given day, please take it as soon as you remember that day.
- Remind your primary care provider that you are participating in REPRIEVE.
- Please call your research team if you have any study related questions.



Your participation matters!

By participating in REPRIEVE and completing all study visits, you may be making an **important contribution** to our knowledge of HIV and heart disease that could have lasting benefits for your generation and future generations of people living with HIV.

Thank you to our sponsors:

